Quaratusugene ozeplasmid is under clinical development by Genprex and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Quaratusugene ozeplasmid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Quaratusugene ozeplasmid overview
GPX-001 in combination with erlotinib, osimertinib and pembrolizumab is under development for the treatment of KRAS/STK11 mutated non-small cell lung cancer, small-cell lung cancer, malignant pleural mesothelioma and glioblastoma multiforme (GBM). The drug candidate comprises of cancer-fighting genes which is encapsulated into nanoscale hollow spheres called nanovesicles and administered through intravenous route. It acts by targeting TUSC2 protein and Nitrogen Permease Regulator 2 Like Protein. The drug candidate is being developed based on oncoprex nanovesicle delivery system technology.
The drug candidate was also under development for the treatment of small cell lung cancer, metastatic lung cancer, other solid tumors include head and neck, TNBC, kidney and soft tissue cancer.
Genprex overview
Genprex is a clinical-stage gene therapy company that primarily focuses on developing therapies for patients with cancer and diabetes. The company’s main activities focuses on the development of gene therapies designed to administer disease-fighting genes, providing new treatment options for large patient populations with limited alternatives. Its products include its lead candidate, REQORSA immunogene therapy, and a diabetes gene therapy, GPX-002. Genprex’s products are intended for patients with non-small cell lung cancer, small cell lung cancer, and both Type 1 and Type 2 diabetes. Its proprietary ONCOPREX nanoparticle delivery system is a significant part of its oncology program, and its diabetes gene therapy approach involves a novel infusion process. The company operates in the biotechnology and healthcare sectors, targeting markets with large patient populations in need of advanced treatment options. Genprex is headquartered in Austin, Texas, the US.
For a complete picture of Quaratusugene ozeplasmid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
